The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE

HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen, plasma HIV-1 RNA viral load. NOTE: The term "licensed" referred to an FDA-approved kit, which was required for all IND studies. WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandated that confirmation of the initial test result had to use a test that was different from the one used for the initial assessment. A reactive initial rapid test had to be confirmed by either another type of rapid assay or an E/CIA that was based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), or a Western blot or a plasma HIV-1 RNA viral load. HIV-1 Plasma viral load (VL) greater than 200 copies/mL within 12 months prior to study entry by any US laboratory that had a Clinical Laboratory Improvement Amendments (CLIA) certification or its equivalent, unless the participant had been lost to clinical follow-up (see protocol for more information) and no viral load result was available within the last 12 months.

Evidence of non-adherence to ART according to at least one of the following criteria: Poor virologic response within 18 months prior to study entry (defined as less than 1 log10 decrease in HIV-1 RNA or HIV-1 RNA greater than 200 copies/mL at two time points at least 4 weeks apart) in individuals who had been prescribed ART for at least 6 consecutive months. Lost to clinical follow-up within 18 months prior to study entry with ART non-adherence for greater than or equal to 6 consecutive months. NOTE: Lost to clinical follow-up was defined as either no contact with the provider or missing greater than or equal to 1 appointment in a 6-month period. ART non-adherence was defined as a lapse in ART greater than or equal to 7 days (consecutive or non-consecutive), in the 6-month period where they were lost to clinical follow-up per participant report. No evidence of any clinically relevant RPV or INSTI resistance-associated mutations (see protocol for more information) through commercially available genotypic (or phenotypic, if available) analyses from any laboratory that had a CLIA certification or equivalent within 60 days of study entry (see protocol for more information), nor history of such mutations on review of prior HIV-1 drug resistance tests by the site investigator. For participants in whom a screening HIV-1 conventional genotype could not be resulted by the testing laboratory, review of historical genotypes and treatment history by the IoR could be used to satisfy this criterion as indicated in the protocol. Ability of site clinician, in conjunction with the participant, to construct an oral induction antiretroviral (ARV) regimen that had to include at least three ARVs of which at least two had to be predicted to be fully active. The regimen had to include PI/cobi and/or an INSTI based on screening and/or historic resistance testing. Laboratory values obtained within 60 days prior to study entry by any laboratory that had a CLIA certification or its equivalent: Hemoglobin greater than or equal to 9.0 g/dL Absolute neutrophil count (ANC) greater than or equal to 600/mm^3 Alanine aminotransferase (ALT) less than or equal to 3 x upper limit of normal (ULN) Creatinine Clearance (CrCl) greater than or equal to 50 mL/min estimated by Chronic Kidney Disease Epidemiology Collaboration equation (CKD-Epi). For participants of reproductive potential, a negative serum or urine pregnancy test with a sensitivity of less than or equal to 25 mIU/mL at screening. This was repeated again at study entry. NOTE: Participants were considered to be NOT of reproductive potential if: 1) they had had amenorrhea for at least 12 consecutive months prior to study entry (i.e., who had had no menses within 12 months prior to study entry), and had a documented follicle-stimulating hormone (FSH) greater than 40 IU/mL; OR 2) an FSH level was not available, but they had had 24 consecutive months of amenorrhea (in the absence of medications known to induce amenorrhea); OR 3) they reported having undergone surgical sterilization (e.g., hysterectomy, or bilateral oophorectomy, or bilateral tubal ligation/hysteroscopic tubal occlusion). Contraception Requirements Participants of Reproductive Potential: Participants of reproductive potential, who were participating in sexual activity that could lead to pregnancy, had to agree to use at least one of the listed highly effective methods for contraception from 30 days prior to the first dose of study medication, while receiving the study drugs, and for 30 days after stopping oral medications, or the duration specified in the product label if receiving study drugs not supplied by the study, or 52 weeks after stopping RPV-LA or CAB-LA. Acceptable methods of contraception included: Contraceptive subdermal implant Intrauterine device or intrauterine system Combined estrogen and progestogen oral contraceptive Injectable progestogen Contraceptive vaginal ring Percutaneous contraceptive patches Participants Who Were Not of Reproductive Potential: Participants who were not of reproductive potential were eligible to start study drugs without requiring the use of contraceptives. Any statement of self-reported sterility or that of her partner's had to be entered in the source documents. NOTE A: Acceptable documentation of lack of reproductive potential was the participant's self-reported history of surgical sterilization, menopause, or male partner's azoospermia. NOTE B: ALL participants in the study were to be counseled on safer sexual practices including the use and benefit/risk of effective barrier methods (e.g., male condom) and on the risk of HIV transmission to a partner without HIV. Ability and willingness of participant or legal guardian/representative to provide written informed consent.

Currently pregnant, planning to become pregnant during the study period, or currently breastfeeding. Participants determined by the Site Investigator to have had a high risk of seizures, including participants with an unstable or poorly controlled seizure disorder. NOTE: A participant with a prior history of seizure could have been considered for enrollment if the Investigator believed the risk of seizure recurrence was low. All cases of prior seizure history were to be discussed with the A5359 protocol leadership team ([email protected]) prior to enrollment. Advanced liver disease (as defined by any of the following: presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice), known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones) OR history of liver cirrhosis. Chronic Hepatitis C (HCV) with planned or anticipated use of anti-HCV therapy prior to the completion of Step 2. History of or current active hepatitis B (HBV) infection defined as a positive HBV surface antigen test or any detectable HBV DNA in participants with isolated HBcAb and HBV DNA as follows: Participants positive for HBsAg were excluded. Participants negative for anti-HBs but positive for anti-HBc (negative HBsAg status) and any detectable HBV DNA were excluded. NOTE: Participants positive for anti-HBc (negative HBsAg status) and positive for anti-HBs (past and/or current evidence) were immune to HBV and were not excluded. If prior documentation of immunity was available, repeat testing at screening was not required. Current or anticipated need for chronic anti-coagulation therapy. Unwilling to receive injections, or unable to receive gluteal injections. Tattoo or other condition over the gluteus region, which could have interfered with the interpretation of injection site reaction. Previous use of CAB. Any acute or serious illness, within 7 days prior to entry, requiring systemic treatment and/or hospitalization that could have rendered the participant unable to receive study medication, in the opinion of the site investigator. QTc greater than 450 ms using either Bazett or Fridericia method within 60 days prior to study entry: Whichever method was used at screening had to be used throughout the study period. Any serious medical or psychiatric condition, which could have rendered the participant unable to receive study medication in the opinion of the site investigator. Known allergy/sensitivity or any hypersensitivity to components of study drug(s) or their formulation. Requirement for any medication that was prohibited with a study medication (refer to protocol-specific web page [PSWP]).

Meeting virologic suppression criteria at or after Step 1, week 4, defined as:

• HIV-1 RNA ≤200 copies/mL OR
• HIV-1 RNA of 201-399 copies/mL followed by HIV-1 RNA ≤200 copies/mL by Step 1, week 24. NOTE: The HIV-1 RNA viral load that was used to determine eligibility for randomization had to have been collected within 4 weeks (28 days) of the Step 2 randomization visit.

Permanent discontinuation of study treatment for any reason during Step 1. Participants who never started study treatment in Step 1 (see protocol for more information).

Virologic suppression at or after Step 1, week 4, defined as:

• HIV-1 RNA ≤200 copies/mL OR
• HIV-1 RNA of 201-399 copies/mL followed by HIV-1 RNA ≤200 copies/mL by Step 1, week 24. NOTE: The HIV-1 RNA viral load that was used to determine eligibility for Step 3 had to have been collected within 4 weeks (28 days) of the Step 3 registration visit. Willingness to begin to receive LA ART.

Permanent discontinuation of study treatment for any reason during Step 1. Participants who never started study treatment in Step 1 (see protocol for more information). Currently pregnant, planning to become pregnant during the study period, or currently breastfeeding.

Willingness to continue LA ART (for those in Step 2 Arm A) or begin LA ART (for those in Step 2 Arm B). Step 2 Arm B participants: HIV-1 RNA ≤200 copies/mL at the most recent Step 2 visit OR Confirmation of Virologic Failure visit. NOTE: The HIV-1 RNA viral load that was used to determine eligibility for Step 3 had to have been collected within 4 weeks (28 days) of the Step 3 registration visit.

Permanent discontinuation of study treatment (LA ART for Arm A and oral ART for Arm B) for any reason during Step 2. Confirmed Virologic Failure during Step 2. Step 2 Arm B Participants: Currently pregnant, planning to become pregnant during the study period, or currently breastfeeding. NOTE: Step 2 Arm A participants who became pregnant and were permitted to continue on LA-ART could continue on that regimen in Step 3.

Any participant who had received at least one dose of CAB-LA or RPV-LA AND did not have access to available LA ART through their provider, OR did not wish to continue LA ART.